收费全文 | 5111篇 |
免费 | 242篇 |
国内免费 | 8篇 |
耳鼻咽喉 | 86篇 |
儿科学 | 330篇 |
妇产科学 | 66篇 |
基础医学 | 703篇 |
口腔科学 | 81篇 |
临床医学 | 264篇 |
内科学 | 908篇 |
皮肤病学 | 101篇 |
神经病学 | 318篇 |
特种医学 | 92篇 |
外科学 | 702篇 |
综合类 | 177篇 |
一般理论 | 4篇 |
预防医学 | 394篇 |
眼科学 | 95篇 |
药学 | 622篇 |
中国医学 | 33篇 |
肿瘤学 | 385篇 |
2023年 | 31篇 |
2022年 | 46篇 |
2021年 | 157篇 |
2020年 | 107篇 |
2019年 | 134篇 |
2018年 | 155篇 |
2017年 | 104篇 |
2016年 | 140篇 |
2015年 | 184篇 |
2014年 | 223篇 |
2013年 | 245篇 |
2012年 | 403篇 |
2011年 | 396篇 |
2010年 | 213篇 |
2009年 | 164篇 |
2008年 | 299篇 |
2007年 | 270篇 |
2006年 | 285篇 |
2005年 | 221篇 |
2004年 | 213篇 |
2003年 | 180篇 |
2002年 | 135篇 |
2001年 | 111篇 |
2000年 | 108篇 |
1999年 | 97篇 |
1998年 | 46篇 |
1997年 | 29篇 |
1996年 | 21篇 |
1995年 | 20篇 |
1994年 | 18篇 |
1993年 | 30篇 |
1992年 | 59篇 |
1991年 | 37篇 |
1990年 | 34篇 |
1989年 | 60篇 |
1988年 | 45篇 |
1987年 | 22篇 |
1986年 | 30篇 |
1985年 | 29篇 |
1984年 | 24篇 |
1983年 | 37篇 |
1981年 | 13篇 |
1980年 | 18篇 |
1979年 | 23篇 |
1978年 | 13篇 |
1975年 | 11篇 |
1973年 | 18篇 |
1972年 | 13篇 |
1971年 | 12篇 |
1970年 | 13篇 |
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献While there is evidence of morbidity compression in many countries, temporal patterns of non-communicable diseases (NCDs) in developing countries, such as India, are less clear. Age at onset of disease offers insights to understanding epidemiologic trends and is a key input for public health programs. Changes in age at onset and duration of major NCDs were estimated for 2004 (n = 38,044) and 2018 (n = 43,239) using health surveys from the India National Sample Survey (NSS). Survival regression models were used to compare trends by sociodemographic characteristics. Comparing 2004 to 2018, there were reductions in age at onset and increases in duration for overall and cause-specific NCDs. Median age at onset decreased for NCDs overall (57 to 53 years) and for diabetes, hypertension, heart disease, asthma, mental diseases, eye disease, and bone disease in the range of 2–7 years and increased for cancer, neurological disorders, some genitourinary disorders, and injuries/accidents in the range of 2–14 years. Hazards of NCDs were higher among females for cancers (HR 1.51, 95% CI 1.19–1.90) and neurological disorders (HR 1.18, 95% CI 1.06–1.32) but lower for heart diseases (HR 0.88, 95% CI 0.79–0.97) and injuries/accidents (HR 0.87, 95% CI 0.77–0.99). Hazards were greater among those with lower educational attainment at younger ages and higher educational attainment later in life. Unlike many countries, chronic disease morbidity may be expanding in India for many chronic diseases, indicating excess strain on the health system. Public health programs should focus on early diagnosis and prevention of NCDs.
相似文献